TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02194829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT01185171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD 1839 500mg
Description: Optional Induction chemotherapy:~Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance \[CC\] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.~Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle.
Study: NCT01040715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNFa Kinoid
Description: TNFa kinoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNFa Kinoid
Description: TNFa kinoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNFa Kinoid
Description: TNFa kinoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF kinoid
Description: IM administration 2 or 3 injections within 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF kinoid
Description: IM administration 2 or 3 injections within 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF kinoid
Description: IM administration 2 or 3 injections within 28 days
Study: NCT02960477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience education
Description: A PNE session covers the neurobiology, neurophysiology and processing of pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomedical Education
Description: A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
Study: NCT02536781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyanin
Description: Anti-inflammation gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank gel
Study: NCT03623633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: denosumab 60 milligrams subcutaneously every 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: denosumab 60 milligrams subcutaneously every 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate
Description: alendronate 70 milligrams weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raloxifene
Description: raloxifene 60 milligrams daily
Study: NCT02869841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine continuous infusion
Description: Levobupivacaine continuous infusion to rectus sheath catheters

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine bolus dosing
Description: Levobupivacaine bolus dosing to rectus sheath catheters

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single bolus of levobupivacaine
Description: Levobupivacaine single dose to rectus sheath catheters

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No rectus sheath analgesia
Study: NCT02097459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toremifene
Study: NCT00938587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327 10 mg
Description: PF-04171327 10 mg tablet every day for 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prednisone Placebo
Description: Placebo for Prednisone 5 mg tablet every day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327 25 mg
Description: PF-04171327 25 mg tablet every day for 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prednisone Placebo
Description: Placebo for Prednisone 5 mg tablet every day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 5 mg
Description: Prednisone 5 mg tablet every day for 14 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for PF-04171327
Description: Placebo for PF-04171327 every day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet every day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PF-04171327
Description: Placebo tablet every day for 14 days
Study: NCT01938989

Intervention type: DEVICE
Group type: OTHER
Intervention: Clear clip-on glasses
Description: Clip-on glasses with no light filtering properties

Intervention type: DEVICE
Group type: OTHER
Intervention: Clear clip-on glasses
Description: Clip-on glasses with no light filtering properties

Intervention type: DEVICE
Group type: OTHER
Intervention: Blue light filter clip-on glasses
Description: Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs

Intervention type: DEVICE
Group type: OTHER
Intervention: Blue light filter clip-on glasses
Description: Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
Study: NCT04064255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practical Body Image (session 1 - 7)
Description: Practical body image therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practical Body Image (session 8 - 14)
Description: Twice weekly mirror exposure plus ending session
Study: NCT04441385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: Patients will receive maraviroc 300 mg twice daily for 14 days

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care therapy
Description: Subjects randomized to control group will be on standard care treatment according to the Ministry of Health and Local Guidelines and Protocols.
Study: NCT01354548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBite® Jaw Motion Rehabilitation System™
Description: A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
Study: NCT00933114

Intervention type: PROCEDURE
Intervention: MRI and PET imaging
Description: Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
Study: NCT04877158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Blame and Perspective-Taking Intervention
Description: The intervention is a group therapy that consists of experiential art tasks followed by psychoeducation about social behaviors with weekly homework. There are four sessions, each one week apart.
Study: NCT01715142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
Study: NCT01977027

Intervention type: OTHER
Group type: OTHER
Intervention: Alternate Hand Training or Affected Hand Training
Description: Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.

Intervention type: OTHER
Group type: OTHER
Intervention: Alternate Hand Training or Affected Hand Training
Description: Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
Study: NCT01818609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step reduction
Description: taking less than 1500 steps/d
Study: NCT00715117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, sugar pill
Description: Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
Study: NCT02394522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spatial Repellent product with active ingredient (SHIELD)
Description: Spatial Repellent Product - Passive Emanator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Ingredient
Description: Transfluthrin (Active ingredient)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spatial Repellent product without active ingredient (SHIELD)
Description: Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
Study: NCT02997683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Vibration platform GALILEO
Description: 3 month home based training on whole Body Vibration platform GALILEO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercises at home on the floor
Description: exercises at home on the floor
Study: NCT02576327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: Tropisetron Hydrochloride Injection 5mg (Day 1-6)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tropisetron
Description: Tropisetron Hydrochloride Injection 5mg (Day 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
Study: NCT02643511

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
Description: A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
Study: NCT03774875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg tablets taken orally twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Description: Apremilast 30 mg tablets taken orally twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally twice a day
Study: NCT00450398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YSPSL
Description: YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
Study: NCT05714423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-PCNL
Description: Mini-PCNL will done as follows. A 6 Fr ureteral catheter will be introduced through cystoscopy and dye will be instilled to opacify the pelvicalyceal system. After elaborating the calyceal system through fluoroscopy, selective calyceal will be punctured and tract will be dilated using 16 F sheath. Miniature nephroscope 14 Fr will be then introduced and stones will be fragmented by holmium: YAG laser. Afterwards the collecting system will be examined through nephroscope and fluoroscopic confirmation will be done to ensure complete stone clearance. In all the cases, 6 Fr 24 cm DJ stent will be placed and if remained uneventful, the patient will be discharged on postoperative day 2 with oral antibiotics.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS
Description: RIRS will be performed as follows. In this procedure a double J stent will be placed to dilate the calyceal system 2 weeks prior the surgery. During the procedure, cystoscopy will be done, and 0.035-inch guide wire will be placed in the pelvi-calyceal system. Ureteric access sheath of 12 Fr will be placed and with the help of digital polyscope the stone will be fragmented using Holmium: YAG laser using 220 μm fiber. DJ stent 6F 24 cm will be placed in all the cases. In uneventful surgery patient will be discharged on postoperative day 1 with oral antibiotics
Study: NCT01018732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Meningococcal (MenACWY-CRM) vaccine
Description: All subjects will have blood draws at Day 1, Day 8, and Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Meningococcal (MenACWY-CRM) vaccine
Description: All subjects will have blood draws at Day 1, Day 8, and Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Meningococcal (MenACWY-CRM) vaccine
Description: All subjects will have blood draws at Day 1, Day 8, and Day 29.
Study: NCT00398723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrowband UVB
Description: Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema
Study: NCT00806637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vessel sealing system uvulopalatoplasty (VSSU)
Description: Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
Study: NCT01715142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
Study: NCT00806637

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uvulopalatal flap (UPF)
Description: Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
Study: NCT04287140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus fluid administration
Description: 1000 ml of 0.9% normal saline bolus over one hour
Study: NCT02321267

Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab, aflibercept, pegaptanib, verteporphin
Description: ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
Study: NCT03170843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of plastic ring wound retractor
Description: the experimental arm will use the plastic ring wound retractor for wound protection.
Study: NCT01296594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
Study: NCT02055456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Study: NCT02530398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinobufacini Injection
Description: Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
Study: NCT03668171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell transplantation or placebo infusion via peripheral vein
Description: 0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: mesenchymal stem cell transplantation or placebo infusion via peripheral vein
Description: 0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
Study: NCT05988034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for avacopan
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for avacopan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxacin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for moxifloxacin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for moxifloxacin
Description: Administered orally.
Study: NCT03330964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: Electroacupuncture was administrated immediately after completion of oxaliplatin infusion,once a day for 3 days,30 minutes each time.
Study: NCT03995225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartband automatic smoking detection combined with brief mindfulness interventions
Description: Smartband/smartphone based automatic smoking monitoring, notification and real-time brief mindfulness interventions and learn to work mindfully with cravings and triggers rather than smoke using RAIN prior to smoking episodes.This is a 3 step intervention.
Study: NCT02923193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Lithoplasty® Peripheral Lithoplasty System
Description: The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
Study: NCT01126866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensified chemotherapy (FOLFOXIRI/Bevacizumab)
Description: intensified chemotherapy (FOLFOXIRI/Bevacizumab)
Study: NCT02452554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lorvotuzumab Mertansine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies